GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » EV-to-Revenue

Calithera Biosciences (STU:2CB0) EV-to-Revenue : (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Calithera Biosciences's enterprise value is €-8.62 Mil. Calithera Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00 Mil. Therefore, Calithera Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Calithera Biosciences's EV-to-Revenue or its related term are showing as below:

STU:2CB0's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.37
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Calithera Biosciences's stock price is €0.045. Calithera Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00. Therefore, Calithera Biosciences's PS Ratio for today is .


Calithera Biosciences EV-to-Revenue Historical Data

The historical data trend for Calithera Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences EV-to-Revenue Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 - - -0.53 -

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -1.04 -0.76 - -

Competitive Comparison of Calithera Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Calithera Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's EV-to-Revenue falls into.



Calithera Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Calithera Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-8.615/0
=

Calithera Biosciences's current Enterprise Value is €-8.62 Mil.
Calithera Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences  (STU:2CB0) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Calithera Biosciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.045/0
=

Calithera Biosciences's share price for today is €0.045.
Calithera Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (STU:2CB0) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines